firocoxib has been researched along with 4-butyrolactone in 84 studies
| Studies (firocoxib) | Trials (firocoxib) | Recent Studies (post-2010) (firocoxib) | Studies (4-butyrolactone) | Trials (4-butyrolactone) | Recent Studies (post-2010) (4-butyrolactone) |
|---|---|---|---|---|---|
| 102 | 43 | 71 | 4,456 | 78 | 1,823 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 21 (25.00) | 29.6817 |
| 2010's | 53 (63.10) | 24.3611 |
| 2020's | 10 (11.90) | 2.80 |
| Authors | Studies |
|---|---|
| Andersen, DR; Black, WC; Brideau, C; Hanson, PD; Hickey, GJ; McCann, ME; Zhang, D | 1 |
| Black, WC; Brideau, C; Cunningham, PK; Hickey, GJ; Hora, DF; McCann, ME; Rickes, EL; Zhang, D | 1 |
| Carithers, D; Moldave, K; Ryan, WG | 2 |
| Alva, R; Bell, L; Brooks, KC; Case, J; Conzemius, M; Drag, M; Fleishman, C; Gordon, W; Hanson, PD; Romano, D; Schuessler, J; Shelley, B; Sifferman, R | 1 |
| Clark, TP | 1 |
| Fleishman, C; Hanson, PD; Pollmeier, M; Toulemonde, C | 1 |
| Overgaauw, P | 1 |
| Hanson, PD; Hazewinkel, HA; Pollmeier, M; Theyse, LF; van den Brom, WE | 1 |
| Drag, M; Hanson, PD; Kunkle, BN; Romano, D | 1 |
| Fischer, J; Kvaternick, V; Letendre, L; Tecle, B | 1 |
| Fischer, J; Hanson, PD; Kvaternick, V; Pollmeier, M | 1 |
| Ferreira, TH; Luna, SP; Mantovani, FB; Moutinho, FQ; Salcedo, ES; Steagall, PV | 1 |
| Fischer, J; Kvaternick, V; Malinski, T; Wortmann, J | 1 |
| Alva, R; Bertone, AL; Doucet, MY; Hanson, PD; Hendrickson, D; Hughes, F; Kunkle, B; Macallister, C; McClure, S; Reinemeyer, C; Romano, D; Rossier, Y; Sifferman, R; Vrins, AA; White, G | 1 |
| Budsberg, SC; Punke, JP; Reynolds, LR; Speas, AL | 1 |
| Fischer, JB; Hanson, PD; Kvaternick, VJ; Letendre, LT; McClure, SR; Tessman, RK | 1 |
| Dowling, G; Gallo, P; Regan, L | 1 |
| Back, W; Hanson, PD; MacAllister, CG; Pollmeier, M; van Heel, MC | 1 |
| Blikslager, AT; Campbell, NB; Cook, VL; Meyer, CT | 1 |
| Joubert, KE | 1 |
| Budsberg, SC; Goodman, LA; Reynolds, LR; Torres, BT | 1 |
| Cox, S; Yarbrough, J | 1 |
| Lecoindre, O; Pepin-Richard, C | 1 |
| Camargo, JB; Lorena, SE; Luna, SP; Minto, BW; Mori, ES; Steagall, PV | 1 |
| Asimus, E; Autefage, A; Palissier, FM; Pepin-Richard, C | 1 |
| Dowling, G; Malone, E | 1 |
| Emmerich, IU | 1 |
| Al-Nadaf, S; Budsberg, SC; Cathcart, CJ; Johnston, SA; Reynolds, LR | 1 |
| Cox, S; Doherty, T; Dudenbostel, L; Saleh, M; Sommardahl, C; Yarbrough, J | 1 |
| De Voe, RS; Linder, K; Loomis, MR; McCalla-Martin, A; Stringer, EM; Troan, B | 1 |
| Boston, RC; Carithers, DS; Orsini, JA; Ryan, WG | 1 |
| Fleishman, C; Gross, SJ; Kinoshita, G; Kondo, Y; Matsumoto, S; Otsuki, T; Rosentel, J; Shiba, M; Takashima, K; Yamane, Y | 1 |
| Barton, MH; Budsberg, S; Giguère, S; King, D; Norton, N; Paske, E | 1 |
| Conzemius, MG; Davila, D; Evans, RB; Keeshen, TP | 1 |
| Amicucci, A; Breeding, D; Cox, S; Doherty, T; Kvaternick, V; Reed, K; Siger, L; Sommardahl, C; Villarino, N; Yarbrough, J; Zarabadipour, C | 1 |
| Abramo, F; Albanese, F; Caporali, C; Millanta, F; Vichi, G | 1 |
| Chandler, KJ; Sutton, DG | 1 |
| Kivett, L; Taintor, J; Wright, J | 1 |
| Arthur, RM; Knych, HK; Mitchell, MM; Stanley, SD | 1 |
| Brain, PH; Dunn, AL; Greenwell, CM | 1 |
| Barth, LA; Coetzee, JF; Gehring, R; Stock, ML; Wulf, LW | 1 |
| Crisman, MV; Davis, JL; Hodgson, DR; Hodgson, JL; Hovanessian, N; McKenzie, HC | 1 |
| Delk, KW; Divers, S; Jiménez, DA; Kent, M; Mayer, J; Mejia-Fava, J; Myrna, K | 1 |
| Boos, A; Domosławska, A; Fingerhut, J; Hoffmann, B; Janowski, T; Jurczak, A; Kowalewski, MP; Schuler, G; Zduńczyk, S | 1 |
| Barlow, BM; Blikslager, AT; Curling, A; Davis, JL; Fogle, C; Holland, B; Schirmer, J | 1 |
| Agha, BA; Al Ali, WA; Al Biriki, NA; Al Neaimi, KM; Kamel, AM; Saeed, HM; Sultan, SM; Wasfi, IA | 1 |
| Boos, A; Domosławska, A; Fingerhut, J; Gram, A; Hoffmann, B; Ihle, S; Janowski, T; Jurczak, A; Kowalewski, MP; Schuler, G; Siemieniuch, MJ; Zduńczyk, S | 1 |
| Cullander, RM; Duz, M; Marshall, JF; Parkin, TD | 1 |
| Barth, LA; Coetzee, JF; Gehring, R; Hsu, WH; Millman, ST; Parsons, RL; Stock, ML; Van Engen, NK; Wang, C | 1 |
| Benson, SM; Cox, S; Giguère, S; Macpherson, ML; McNaughten, JW; Pozor, MA | 1 |
| Barry, J; Pavek, T; Reddyjarugu, B; Singh, B; Southard, T | 1 |
| Barton, MH; Clifton, S; Darden, JE; Vandenplas, M | 1 |
| Arenas, C; Granados-Soler, JL; Peña, L; Pérez-Alenza, MD | 1 |
| Phuwapattanachart, P; Thengchaisri, N | 1 |
| Burkett, BN; Fontenot, RL; Hurdle, HM; Thomason, JM; Wills, RW | 1 |
| Cheramie, H; Crisman, MV; Davis, JL; Hodgson, DR; Kvaternick, V; Wilson, KE; Zarabadipour, C | 1 |
| Blikslager, A; Fogle, C; Ziegler, A | 1 |
| Fortier, LA; Goodale, MB; Maylin, GA; Ober, C; Ortved, KF | 1 |
| Conzemius, MG; Heffernan, AE; Katz, EM; Rendahl, AK; Sun, Y | 1 |
| Chamoun-Emanuelli, AM; Cohen, ND; Dockery, HJ; Richardson, LM; Whitfield-Cargile, CM | 1 |
| Ajami, NJ; Chamoun-Emanuelli, AM; Cohen, ND; Dockery, HJ; Richardson, LM; Whitfield-Cargile, CM | 1 |
| Blikslager, AT; Burke, MJ; Cook, VL; Davis, JL; Fogle, CA; Freeman, CK; Southwood, LL; Ziegler, AL | 1 |
| Alvarenga, MA; Andrade, VP; Fernandes, CB; Freitas-Dell'Aqua, CP; Nichi, M; Okada, CTC; Papa, FO | 1 |
| Freeman, DE | 1 |
| Blikslager, AT; Burke, M; Fogle, CA; Ziegler, AL | 1 |
| Boos, A; Gram, A; Hoffmann, B; Janowski, T; Kowalewski, MP; Nowaczyk, R; Tavares Pereira, M | 1 |
| Coetzee, JF; Cooper, VL; Jaberi-Douraki, M; Kleinhenz, K; Kleinhenz, MD; Lechtenberg, K; Mazloom, R; Schieber, T; Seagen, J; Sidhu, PK; Wulf, LW | 1 |
| Ibancovichi-Camarillo, JA; Ramírez-Uribe, JM; Rangel-Nava, A; Recillas-Morales, S; Sánchez-Aparicio, P; Venebra-Muñoz, A | 1 |
| Bruni, G; Celestini, P; Chiesa, E; Friuli, V; Maggi, L; Pisani, S; Sakaj, M | 1 |
| Alvarenga, MA; Correal, SB; Cyrino, M; Dell'Aqua, JA; Freitas-Dell'Aqua, CP; Friso, AM; Miró, J; Papa, FO; Segabinazzi, LGTM; Teoro do Carmo, M | 1 |
| Barrell, EA; Caixeta, LS; Coetzee, JF; KuKanich, B; Stuart, AK | 1 |
| Beugnet, F; de Salazar Alcalá, AG; Dehman, A; Gioda, L | 1 |
| Beale, B; Jarudecha, T; Kashemsant, N; Kwananocha, I; Lascelles, BDX; Lekcharoensuk, C; Peirone, B; Vijarnsorn, M | 1 |
| Bauck, AG; Gilliam, LL; Kembel, SL; Schoonover, MJ; Taylor, JD; Young, JM | 1 |
| Coetzee, JF; Fitzgerald, AH; Kleinhenz, MD; Odland, C; Sidhu, PK; Williams, TE; Wulf, LW; Zhang, Y | 1 |
| Gao, A; Kvaternick, V; Latli, B; Pennino, S; Song, J; Tecle, B; Yee, NK | 1 |
| Colgan, SA; Karamatic, SL; Li, EC; Morris, TH; Paine, SW; Zahra, PW | 1 |
| Albernaz, AP; Di Filippo, PA; Gobbi, FP; Lemos, GB; Martins, CB; Mello, LM; Quirino, CR | 1 |
| Benson, SM; Berghaus, LJ; Berghaus, RD; Burden, CA; Giguère, S; Hart, KA; Hayna, JT; Horohov, DW; Kelleman, AA; Lyle, SK; Macpherson, ML; Mallicote, MF; Pozor, MA; Randell, SA; Varner, JC | 1 |
| Geum, M; Kim, HJ; Ko, HY; Na, YJ | 1 |
| Bennett, TE; Pavek, TJ; Schwark, WS; Singh, B | 1 |
| Gardhouse, S; Hocker, SE; Kleinhenz, M; Montgomery, SR; Porting, A; Rooney, T; Weeder, M; Zhang, Y | 1 |
| Del Castillo, J; Delsart, A; Drag, M; Frezier, M; Lussier, B; Martel-Pelletier, J; Moreau, M; Otis, C; Pelletier, JP; Troncy, E | 1 |
4 review(s) available for firocoxib and 4-butyrolactone
| Article | Year |
|---|---|
The clinical pharmacology of cyclooxygenase-2-selective and dual inhibitors.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carbazoles; Cats; Cyclooxygenase 2 Inhibitors; Dogs; Etodolac; Meloxicam; Pain; Pain Measurement; Pyrazoles; Sulfones; Thiazines; Thiazoles | 2006 |
[New drugs for horses and production animals in 2010].
Topics: 4-Butyrolactone; Aminoacetonitrile; Animals; Animals, Domestic; Anthelmintics; Anti-Bacterial Agents; Cattle; Chickens; Cyclooxygenase 2 Inhibitors; Dopamine Agonists; Doxycycline; Germany; Horses; Macrolides; Pergolide; Sheep; Sulfones; Swine; Turkeys; Veterinary Drugs | 2011 |
Update on the use of cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs in horses.
Topics: 4-Butyrolactone; Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Drug Compounding; Horse Diseases; Horses; Species Specificity; Sulfones; Veterinary Drugs | 2017 |
Pharmacological Regulation in the USA and Pharmacokinetics Parameters of Firocoxib, a Highly Selective Cox-2, by Pain Management in Horses.
Topics: 4-Butyrolactone; Animals; Cyclooxygenase 2; Horses; Pain Management; Sulfones; United States | 2019 |
38 trial(s) available for firocoxib and 4-butyrolactone
| Article | Year |
|---|---|
Clinical effectiveness and safety of a new NSAID, firocoxib: a 1,000 dog study.
Topics: 4-Butyrolactone; Age Factors; Animals; Anti-Inflammatory Agents, Non-Steroidal; Dog Diseases; Dogs; Female; Male; Osteoarthritis; Safety; Sex Factors; Sulfones; Treatment Outcome | 2006 |
Efficacy and safety of firocoxib in the management of canine osteoarthritis under field conditions.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Dog Diseases; Dogs; Etodolac; Female; Lameness, Animal; Male; Osteoarthritis; Range of Motion, Articular; Safety; Sulfones; Treatment Outcome | 2006 |
Clinical evaluation of firocoxib and carprofen for the treatment of dogs with osteoarthritis.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carbazoles; Dog Diseases; Dogs; Double-Blind Method; Female; Male; Osteoarthritis; Sulfones; Tablets; Treatment Outcome | 2006 |
Comparison of the effects of firocoxib, carprofen and vedaprofen in a sodium urate crystal induced synovitis model of arthritis in dogs.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Carbazoles; Cross-Over Studies; Dog Diseases; Dogs; Female; Lameness, Animal; Male; Naphthalenes; Propionates; Sulfones; Synovitis; Time Factors; Uric Acid | 2008 |
Firocoxib efficacy preventing urate-induced synovitis, pain, and inflammation in dogs.
Topics: 4-Butyrolactone; Animals; Carbazoles; Cyclooxygenase 2 Inhibitors; Dog Diseases; Dogs; Female; Lameness, Animal; Male; Meloxicam; Severity of Illness Index; Sulfonamides; Sulfones; Synovitis; Thiazines; Thiazoles; Treatment Outcome; Uric Acid | 2007 |
Pharmacokinetics and metabolism of orally administered firocoxib, a novel second generation coxib, in horses.
Topics: 4-Butyrolactone; Administration, Oral; Animals; Area Under Curve; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Female; Horses; Injections, Intravenous; Male; Sulfones | 2007 |
Evaluation of the adverse effects of oral firocoxib in healthy dogs.
Topics: 4-Butyrolactone; Administration, Oral; Animals; Blood Chemical Analysis; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Dog Diseases; Dogs; Drug Hypersensitivity; Endoscopy, Gastrointestinal; Female; Male; Occult Blood; Sulfones | 2007 |
Comparison of efficacy and safety of paste formulations of firocoxib and phenylbutazone in horses with naturally occurring osteoarthritis.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Female; Horse Diseases; Horses; Lameness, Animal; Male; Osteoarthritis; Phenylbutazone; Range of Motion, Articular; Severity of Illness Index; Sulfones; Time Factors; Treatment Outcome | 2008 |
Effects of firocoxib, meloxicam, and tepoxalin on prostanoid and leukotriene production by duodenal mucosa and other tissues of osteoarthritic dogs.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Dog Diseases; Dogs; Duodenum; Female; Intestinal Mucosa; Leukotrienes; Male; Meloxicam; Osteoarthritis; Prostaglandins; Pyrazoles; Sulfones; Synovial Fluid; Thiazines; Thiazoles | 2008 |
The use of force plate measurements to titrate the dosage of a new COX-2 inhibitor in lame horses.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biomechanical Phenomena; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Female; Forelimb; Horse Diseases; Horses; Lameness, Animal; Male; Pressure; Sulfones | 2009 |
The effects of firocoxib (Previcox) in geriatric dogs over a period of 90 days.
Topics: 4-Butyrolactone; Aging; Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Chemical Analysis; Dog Diseases; Dogs; Female; Lameness, Animal; Male; Osteoarthritis; Pain; Severity of Illness Index; Sulfones; Treatment Outcome | 2009 |
Post-operative analgesic effects of butorphanol or firocoxib administered to dogs undergoing elective ovariohysterectomy.
Topics: 4-Butyrolactone; Analgesics, Opioid; Animals; Butorphanol; Dogs; Female; Hysterectomy; Ovariectomy; Pain Measurement; Pain, Postoperative; Single-Blind Method; Sulfones | 2011 |
Efficacy of ABT-116, an antagonist of transient receptor potential vanilloid type 1, in providing analgesia for dogs with chemically induced synovitis.
Topics: 4-Butyrolactone; Analgesia; Animals; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Female; Indazoles; Injections, Intra-Articular; Lameness, Animal; Male; Phenylurea Compounds; Stifle; Sulfones; Synovitis; TRPV Cation Channels; Uric Acid | 2012 |
Pharmacokinetics of firocoxib and its interaction with enrofloxacin in horses.
Topics: 4-Butyrolactone; Administration, Oral; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Drug Interactions; Enrofloxacin; Female; Fluoroquinolones; Half-Life; Horses; Sulfones | 2012 |
Evaluation of oral administration of firocoxib for the management of musculoskeletal pain and lameness associated with osteoarthritis in horses.
Topics: 4-Butyrolactone; Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cross-Sectional Studies; Cyclooxygenase 2 Inhibitors; Female; Horse Diseases; Horses; Lameness, Animal; Male; Musculoskeletal Pain; Osteoarthritis; Pain Management; Sulfones | 2012 |
Efficacy and safety of firocoxib for the treatment of pain associated with soft tissue surgery in dogs under field conditions in Japan.
Topics: 4-Butyrolactone; Animals; Cyclooxygenase Inhibitors; Dogs; Double-Blind Method; Least-Squares Analysis; Pain Measurement; Pain, Postoperative; Sulfones | 2012 |
Efficacy of cyclo-oxygenase inhibition by two commercially available firocoxib products in horses.
Topics: 4-Butyrolactone; Administration, Oral; Animals; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Dinoprostone; Dosage Forms; Horses; Sulfones | 2014 |
Comparison of the analgesic efficacy of perioperative firocoxib and tramadol administration in dogs undergoing tibial plateau leveling osteotomy.
Topics: 4-Butyrolactone; Animals; Dog Diseases; Dogs; Female; Hydrocortisone; Male; Osteotomy; Pain Measurement; Pain, Postoperative; Sulfones; Time Factors; Tramadol | 2013 |
Clinical outcome and cyclo-oxygenase-2 expression in five dogs with solar dermatitis/actinic keratosis treated with firocoxib.
Topics: 4-Butyrolactone; Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dog Diseases; Dogs; Female; Gene Expression Regulation, Enzymologic; Keratosis, Actinic; Male; Sulfones | 2013 |
Detection and pharmacokinetics of three formulations of firocoxib following multiple administrations to horses.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chemistry, Pharmaceutical; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Horses; Male; Sulfones | 2014 |
Pharmacokinetics and safety of firocoxib after oral administration of repeated consecutive doses to neonatal foals.
Topics: 4-Butyrolactone; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Drug Administration Schedule; Horses; Sulfones | 2014 |
In vivo investigations on luteotropic activity of prostaglandins during early diestrus in nonpregnant bitches.
Topics: 3-Hydroxysteroid Dehydrogenases; 4-Butyrolactone; Animals; Corpus Luteum; Dogs; Estrous Cycle; Female; Gene Expression Regulation, Enzymologic; Ovulation; Progesterone; Prostaglandin Antagonists; RNA, Messenger; Sulfones | 2014 |
Pharmacokinetics and pharmacodynamics of three formulations of firocoxib in healthy horses.
Topics: 4-Butyrolactone; Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cross-Over Studies; Dinoprostone; Horses; Injections, Intravenous; Ointments; Sulfones; Tablets; Thromboxane B2 | 2015 |
Formation of the early canine CL and the role of prostaglandin E2 (PGE2) in regulation of its function: an in vivo approach.
Topics: 4-Butyrolactone; Animals; Corpus Luteum; Dinoprost; Dinoprostone; Dogs; Female; Gene Expression Regulation; Intramolecular Oxidoreductases; Male; Prostaglandin-E Synthases; Receptors, Prostaglandin; Sulfones | 2015 |
The effects of firocoxib on cautery disbudding pain and stress responses in preweaned dairy calves.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Cattle; Cautery; Female; Horns; Hydrocortisone; Male; Neurotransmitter Agents; Pain; Substance P; Sulfones | 2015 |
Disposition of firocoxib in late pregnant and early postpartum mares.
Topics: 4-Butyrolactone; Animals; Area Under Curve; Cyclooxygenase 2 Inhibitors; Female; Horses; Postpartum Period; Pregnancy; Pregnancy, Animal; Sulfones; Tissue Distribution | 2016 |
Effects of Firocoxib, Flunixin Meglumine, and Phenylbutazone on Platelet Function and Thromboxane Synthesis in Healthy Horses.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Platelets; Clonixin; Cross-Over Studies; Female; Horses; Male; Phenylbutazone; Sulfones; Thromboxanes | 2016 |
Once daily oral extended-release hydrocodone as analgesia following tibial plateau leveling osteotomy in dogs.
Topics: 4-Butyrolactone; Analgesia; Animals; Anterior Cruciate Ligament Injuries; Delayed-Action Preparations; Dogs; Female; Hydrocodone; Male; Osteotomy; Pain Management; Pain, Postoperative; Prospective Studies; Sulfones; Tibia | 2018 |
Multicentre, blinded, randomised clinical trial comparing the use of flunixin meglumine with firocoxib in horses with small intestinal strangulating obstruction.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Clonixin; Female; Horse Diseases; Horses; Intestinal Obstruction; Male; Pain, Postoperative; Random Allocation; Sulfones | 2019 |
The effect of flunixin meglumine, firocoxib and meloxicam on the uterine mobility of equine embryos.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Clonixin; Embryo, Mammalian; Female; Horses; Meloxicam; Pregnancy; Prostaglandins; Sulfones; Ultrasonography, Prenatal | 2019 |
Prostaglandin-mediated effects in early canine corpus luteum: In vivo effects on vascular and immune factors.
Topics: 4-Butyrolactone; Animals; Corpus Luteum; Cyclooxygenase 2 Inhibitors; Dogs; Female; Gene Expression Regulation; Immunologic Factors; Prostaglandins; Receptors, Estrogen; RNA, Messenger; Sulfones; Transcriptome | 2019 |
Transmammary delivery of firocoxib to piglets reduces stress and improves average daily gain after castration, tail docking, and teeth clipping1.
Topics: 4-Butyrolactone; Animal Welfare; Animals; Anti-Inflammatory Agents, Non-Steroidal; Female; Hydrocortisone; Injections, Intramuscular; Lactation; Male; Orchiectomy; Pain; Pregnancy; Random Allocation; Sulfones; Swine; Tooth; Weaning | 2019 |
Periovulatory administration of firocoxib did not alter ovulation rates and mitigated post-breeding inflammatory response in mares.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Breeding; Cross-Over Studies; Drug Administration Schedule; Endometritis; Estrous Cycle; Female; Horse Diseases; Horses; Inflammation; Insemination, Artificial; Male; Ovulation; Pregnancy; Pregnancy Rate; Sulfones; Treatment Outcome | 2019 |
Pharmacokinetics and bioavailability of oral firocoxib in adult, mixed-breed goats.
Topics: 4-Butyrolactone; Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Cross-Over Studies; Female; Goats; Half-Life; Sulfones | 2019 |
Assessment of the efficacy of firocoxib (Previcox®) and grapiprant (Galliprant®) in an induced model of acute arthritis in dogs.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Dog Diseases; Dogs; Lameness, Animal; Random Allocation; Sulfones; Sulfonylurea Compounds; Uric Acid | 2019 |
The effectiveness of marine based fatty acid compound (PCSO-524) and firocoxib in the treatment of canine osteoarthritis.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Dinoprostone; Dog Diseases; Dogs; Double-Blind Method; Drug Therapy, Combination; Fatty Acids, Unsaturated; Female; Gait; Male; Osteoarthritis; Pain; Pain Measurement; Prospective Studies; Sulfones | 2019 |
Efficacy of orally administered gabapentin in horses with chronic thoracic limb lameness.
Topics: 4-Butyrolactone; Analgesics; Animals; Chronic Disease; Cross-Over Studies; Drug Therapy, Combination; Female; Gabapentin; Horse Diseases; Horses; Lameness, Animal; Male; Sulfones | 2020 |
Pharmacokinetics and tissue concentrations of firocoxib in sows following oral administration.
Topics: 4-Butyrolactone; Administration, Oral; Analgesics; Animals; Area Under Curve; Biological Availability; Cross-Over Studies; Female; Half-Life; Sulfones; Swine | 2020 |
42 other study(ies) available for firocoxib and 4-butyrolactone
| Article | Year |
|---|---|
In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in dogs with experimentally induced synovitis.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carbazoles; Cyclooxygenase Inhibitors; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Sulfonamides; Sulfones; Synovitis | 2004 |
In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in cats with lipopolysaccharide-induced pyrexia.
Topics: 4-Butyrolactone; Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cat Diseases; Cats; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Fever; In Vitro Techniques; Injections, Intravenous; Ketoprofen; Lipopolysaccharides; Male; Prostaglandin-Endoperoxide Synthases; Sulfones | 2005 |
[European symposium about osteoarthritis in a dog].
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Dog Diseases; Dogs; Europe; Osteoarthritis; Physical Therapy Modalities; Sulfones; Treatment Outcome | 2007 |
Automated liquid chromatography-tandem mass spectrometry method for the analysis of firocoxib in urine and plasma from horse and dog.
Topics: 4-Butyrolactone; Animals; Chromatography, Liquid; Dogs; Horses; Molecular Structure; Reproducibility of Results; Sulfones; Tandem Mass Spectrometry | 2007 |
Quantitative HPLC-UV method for the determination of firocoxib from horse and dog plasma.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chromatography, High Pressure Liquid; Dogs; Horses; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Sulfones; Therapeutic Equivalency | 2007 |
Switching NSAIDs in practice: insights from the Previcox (firocoxib) Experience Trial.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Databases, Factual; Dogs; Drug Administration Schedule; Osteoarthritis; Patient Selection; Research Design; Retrospective Studies; Sulfones; Veterinary Drugs | 2007 |
Pharmacokinetics of firocoxib after administration of multiple consecutive daily doses to horses.
Topics: 4-Butyrolactone; Administration, Oral; Animals; Chromatography, Liquid; Dose-Response Relationship, Drug; Female; Horses; Injections, Intravenous; Male; Sulfones; Tandem Mass Spectrometry | 2008 |
Confirmatory analysis of firocoxib in bovine milk by rapid resolution liquid chromatography tandem mass spectrometry.
Topics: 4-Butyrolactone; Animals; Cattle; Chromatography, Liquid; Milk; Reproducibility of Results; Sulfones; Tandem Mass Spectrometry | 2009 |
Effect of firocoxib or flunixin meglumine on recovery of ischemic-injured equine jejunum.
Topics: 4-Butyrolactone; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Blotting, Western; Clonixin; Cyclooxygenase 1; Cyclooxygenase 2; Eicosanoids; Electrophoresis, Polyacrylamide Gel; Horse Diseases; Horses; Ischemia; Jejunal Diseases; Sulfones; Thromboxane B2 | 2009 |
Effects of firocoxib, meloxicam, and tepoxalin administration on eicosanoid production in target tissues of healthy cats.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cats; Cross-Over Studies; Cyclooxygenase Inhibitors; Dinoprostone; Duodenum; Eicosanoids; Gastric Mucosa; Intestinal Mucosa; Kinetics; Leukotriene B4; Male; Meloxicam; Orchiectomy; Pyrazoles; Reference Values; Sulfones; Thiazines; Thiazoles | 2010 |
Determination of firocoxib in equine plasma using high performance liquid chromatography.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chromatography, High Pressure Liquid; Drug Stability; Horses; Linear Models; Reproducibility of Results; Sensitivity and Specificity; Sulfonamides; Sulfones | 2011 |
Tolerance of firocoxib in dogs with osteoarthritis during 90 days.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Creatinine; Dog Diseases; Dogs; Female; Male; Osteoarthritis; Sulfones; Treatment Outcome; Urea | 2011 |
Long-term efficacy and safety of firocoxib in the treatment of dogs with osteoarthritis.
Topics: 4-Butyrolactone; Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Dog Diseases; Dogs; Female; Lameness, Animal; Male; Osteoarthritis; Prospective Studies; Severity of Illness Index; Sulfones; Treatment Outcome | 2011 |
Analytical strategy for the confirmatory analysis of the non-steroidal anti-inflammatory drugs firocoxib, propyphenazone, ramifenazone and piroxicam in bovine plasma by liquid chromatography tandem mass spectrometry.
Topics: 4-Butyrolactone; Acetonitriles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Calibration; Cattle; Chromatography, Liquid; Hexanes; Piroxicam; Pyrazoles; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Sodium Chloride; Spectrometry, Mass, Electrospray Ionization; Sulfones; Tandem Mass Spectrometry | 2011 |
Vesiculobullous skin reaction temporally related to firocoxib treatment in a white rhinoceros (Ceratotherium simum).
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Drug Eruptions; Female; Lameness, Animal; Perissodactyla; Skin Diseases, Vesiculobullous; Sulfones | 2012 |
Disposition of firocoxib in equine plasma after an oral loading dose and a multiple dose regimen.
Topics: 4-Butyrolactone; Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Half-Life; Horses; Sulfones; Time Factors | 2013 |
The dilemmas of medicine selection for equine veterinarians.
Topics: 4-Butyrolactone; Animals; Cyclooxygenase 2 Inhibitors; Dinoprostone; Horses; Sulfones | 2014 |
Evaluation of the safety of a combination of oral administration of phenylbutazone and firocoxib in horses.
Topics: 4-Butyrolactone; Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Proteins; Creatinine; Drug Therapy, Combination; Horse Diseases; Horses; Kidney Diseases; Phenylbutazone; Prostaglandin-Endoperoxide Synthases; Sulfones | 2014 |
Metaphyseal osteopathy in three Australian Kelpie siblings.
Topics: 4-Butyrolactone; Animals; Australia; Bone Diseases, Developmental; Dog Diseases; Dogs; Fatal Outcome; Female; Histocytochemistry; Lameness, Animal; Male; Prednisolone; Radiography; Siblings; Sulfones | 2014 |
Pharmacokinetics of firocoxib in preweaned calves after oral and intravenous administration.
Topics: 4-Butyrolactone; Administration, Intravenous; Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Biological Availability; Cattle; Cattle Diseases; Female; Half-Life; Horns; Male; Pain; Sulfones; Weaning | 2014 |
Diagnostic imaging of peripheral vestibular disease in a Chinese goose (Anser cygnoides).
Topics: 4-Butyrolactone; Animals; Anseriformes; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Bird Diseases; Clindamycin; Evoked Potentials, Auditory, Brain Stem; Gram-Positive Bacterial Infections; Male; Meloxicam; Radiography; Sulfones; Thiazines; Thiazoles; Vestibular Diseases | 2014 |
Pharmacokinetics and metabolism study of firocoxib in camels after intravenous administration by using high-resolution bench-top orbitrap mass spectrometry.
Topics: 4-Butyrolactone; Administration, Intravenous; Animals; Camelus; Mass Spectrometry; Sulfones | 2015 |
Effect of flunixin meglumine and firocoxib on ex vivo cyclooxygenase activity in horses undergoing elective surgery.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Clonixin; Cyclooxygenase 1; Cyclooxygenase 2; Elective Surgical Procedures; Female; Horses; Male; Sulfones | 2015 |
Analgesic Efficacy of Firocoxib, a Selective Inhibitor of Cyclooxygenase 2, in a Mouse Model of Incisional Pain.
Topics: 4-Butyrolactone; Analgesics, Opioid; Animals; Buprenorphine; Cyclooxygenase 2 Inhibitors; Female; Hyperalgesia; Mice; Mice, Inbred C57BL; Pain, Postoperative; Random Allocation; Rodent Diseases; Specific Pathogen-Free Organisms; Sulfones | 2015 |
Effect of firocoxib on cyclooxygenase 2, microsomal prostaglandin E2 synthase 1, and cytosolic phospholipase A2 gene expression in equine mononuclear cells.
Topics: 4-Butyrolactone; Animals; Centrifugation, Density Gradient; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytosol; Dinoprostone; Gene Expression Regulation; Horses; Intramolecular Oxidoreductases; Leukocytes, Mononuclear; Lipopolysaccharides; Membrane Proteins; Microsomes; Phospholipases A2; Polymerase Chain Reaction; Prostaglandin-E Synthases; Sulfones | 2015 |
Adjuvant therapy for highly malignant canine mammary tumours: Cox-2 inhibitor versus chemotherapy: a case-control prospective study.
Topics: 4-Butyrolactone; Animals; Antineoplastic Agents; Case-Control Studies; Chemotherapy, Adjuvant; Cyclooxygenase 2 Inhibitors; Dog Diseases; Dogs; Female; Mammary Neoplasms, Animal; Mitoxantrone; Prospective Studies; Sulfones; Treatment Outcome | 2016 |
Analgesic efficacy of oral firocoxib in ovariohysterectomized cats.
Topics: 4-Butyrolactone; Administration, Oral; Analgesia; Analgesics; Animals; Cats; Female; Hysterectomy; Ovariectomy; Pain Measurement; Sulfones | 2017 |
Pharmacokinetics of firocoxib after intravenous administration of multiple consecutive doses in neonatal foals.
Topics: 4-Butyrolactone; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Chromatography, High Pressure Liquid; Drug Administration Schedule; Female; Horses; Injections, Intravenous; Male; Sulfones | 2017 |
Plasma firocoxib concentrations after intra-articular injection of autologous conditioned serum prepared from firocoxib positive horses.
Topics: 4-Butyrolactone; Animals; Blood Transfusion, Autologous; Cyclooxygenase 2 Inhibitors; Female; Horse Diseases; Horses; Injections, Intra-Articular; Joint Diseases; Limit of Detection; Male; Sulfones | 2017 |
Effect of selective versus nonselective cyclooxygenase inhibitors on gastric ulceration scores and intestinal inflammation in horses.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Feces; Gastrointestinal Diseases; Horse Diseases; Horses; Inflammation; Peroxidase; Phenylbutazone; Random Allocation; Stomach Ulcer; Sulfones | 2018 |
Differential effects of selective and non-selective cyclooxygenase inhibitors on fecal microbiota in adult horses.
Topics: 4-Butyrolactone; Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Feces; Horses; Humans; Metagenome; Microbiota; Phenylbutazone; RNA, Ribosomal, 16S; Sulfones | 2018 |
Letter to the Editor: Multicentre, blinded, randomised clinical trial comparing the use of flunixin meglumine with firocoxib in horses with small intestinal strangulating obstruction.
Topics: 4-Butyrolactone; Animals; Clonixin; Horses; Sulfones | 2019 |
Letter to the Editor: Bias in statistics or bias in equine veterinary medicine?
Topics: 4-Butyrolactone; Animals; Clonixin; Horses; Sulfones | 2019 |
Improvement of the Firocoxib Dissolution Performance Using Electrospun Fibers Obtained from Different Polymer/Surfactant Associations.
Topics: 4-Butyrolactone; Cyclooxygenase 2 Inhibitors; Drug Carriers; Nanofibers; Polymers; Solubility; Spectroscopy, Fourier Transform Infrared; Sulfones; Surface-Active Agents; Thermodynamics | 2019 |
Synthesis of stable isotope-labelled firocoxib.
Topics: 4-Butyrolactone; Animals; Chemistry Techniques, Synthetic; Dogs; Horses; Isotope Labeling; Radiochemistry; Sulfones | 2020 |
Pharmacokinetics of carprofen and firocoxib for medication control in racing greyhounds.
Topics: 4-Butyrolactone; Animals; Carbazoles; Dogs; Sulfones | 2020 |
Effects of Flunixin Meglumine, Firocoxib, and Meloxicam in Equines After Castration.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Clonixin; Horses; Male; Meloxicam; Sulfones | 2020 |
Evidence for anti-inflammatory effects of firocoxib administered to mares with experimentally induced placentitis.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents; Cyclooxygenase 2 Inhibitors; Female; Horse Diseases; Horses; Inflammation; Interleukin-6; Matrix Metalloproteinase 1; Placenta; Placenta Diseases; Pregnancy; Prostaglandins; Sulfones; Tumor Necrosis Factor-alpha | 2021 |
Cutaneous adverse drug reaction in a dog following firocoxib treatment.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Dog Diseases; Dogs; Drug-Related Side Effects and Adverse Reactions; Female; Sulfones | 2021 |
Comparison of Nociceptive Effects of Buprenorphine, Firocoxib, and Meloxicam in a Plantar Incision Model in Sprague-Dawley Rats.
Topics: 4-Butyrolactone; Animals; Buprenorphine; Female; Hyperalgesia; Male; Meloxicam; Nociception; Pain, Postoperative; Rats; Rats, Sprague-Dawley; Sulfones | 2021 |
Pharmacokinetics and ex vivo pharmacodynamics of oral firocoxib administration in New Zealand White rabbits (Oryctolagus cuniculus).
Topics: 4-Butyrolactone; Administration, Oral; Animals; Cyclooxygenase 2; Dogs; Rabbits; Sulfones | 2022 |
Development of Two Innovative Performance-Based Objective Measures in Feline Osteoarthritis: Their Reliability and Responsiveness to Firocoxib Analgesic Treatment.
Topics: 4-Butyrolactone; Analgesics; Animals; Cats; Osteoarthritis; Reproducibility of Results; Sulfones | 2022 |